The March towards a Vaccine for Congenital CMV: Rationale and Models
- PMID: 26866914
- PMCID: PMC4750955
- DOI: 10.1371/journal.ppat.1005355
The March towards a Vaccine for Congenital CMV: Rationale and Models
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection.Semin Pediatr Infect Dis. 2002 Jul;13(3):196-204. doi: 10.1053/spid.2002.125863. Semin Pediatr Infect Dis. 2002. PMID: 12199616 Review.
-
Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.J Clin Virol. 2008 Mar;41(3):224-30. doi: 10.1016/j.jcv.2007.10.008. Epub 2007 Dec 3. J Clin Virol. 2008. PMID: 18060834 Review.
-
Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.Vaccine. 2015 Jul 31;33(32):4013-8. doi: 10.1016/j.vaccine.2015.06.019. Epub 2015 Jun 13. Vaccine. 2015. PMID: 26079615 Free PMC article.
-
Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.Vaccine. 2016 Apr 12;34(17):1993-9. doi: 10.1016/j.vaccine.2016.03.005. Epub 2016 Mar 10. Vaccine. 2016. PMID: 26973071
-
Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.J Infect Dis. 2004 Apr 15;189(8):1374-81. doi: 10.1086/382751. Epub 2004 Apr 1. J Infect Dis. 2004. PMID: 15073673
Cited by
-
Multiple biological characteristics and functions of intestinal biofilm extracellular polymers: friend or foe?Front Microbiol. 2024 Aug 19;15:1445630. doi: 10.3389/fmicb.2024.1445630. eCollection 2024. Front Microbiol. 2024. PMID: 39224216 Free PMC article. Review.
-
Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.Methods Mol Biol. 2021;2244:403-463. doi: 10.1007/978-1-0716-1111-1_19. Methods Mol Biol. 2021. PMID: 33555597
-
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.EBioMedicine. 2019 Dec;50:45-54. doi: 10.1016/j.ebiom.2019.11.005. Epub 2019 Nov 15. EBioMedicine. 2019. PMID: 31735553 Free PMC article.
-
Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy.Front Immunol. 2017 Oct 13;8:1294. doi: 10.3389/fimmu.2017.01294. eCollection 2017. Front Immunol. 2017. PMID: 29163461 Free PMC article. Review.
-
Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?Microbes Infect. 2023 Jan-Feb;25(1-2):105078. doi: 10.1016/j.micinf.2022.105078. Epub 2022 Nov 23. Microbes Infect. 2023. PMID: 36435367 Free PMC article.
References
-
- Schleiss M. R., and Heineman T. C. 2005. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381–406. - PubMed
-
- Lilleri D., Fornara C., Furione M., Zavattoni M., Revello M.G., and Gerna G. 2007. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195: 1062–1070. 10.1086/512245 - DOI - PubMed
-
- Lilleri D., Kabanova A., Revello M. G., Percivalle E., Sarasini A., Genini E, Sallusto F., Lanzavecchia A., Corti D. and Gerna G. 2013. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS ONE. 8:e59863 10.1371/journal.pone.0059863 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical